fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Pancrelipase equivalent to lipase & amylase & protease

All products: Limited Use (codes 124, 125, 126)

Viokace · DIN 02241933 · 16 mg · tablet

Limited Use, Reason for Use code 124, 125, 126 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 124, 125, 126 required
Write on scriptone applicable Reason for Use code, 124 or 125 or 126 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 124, 125, 126
Reason for Use code 124 Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection). Coverage limit: LU Authorization Period: Indefinite Reason for Use code 125 Replacement therapy for pancreatic insufficiency due to chronic pancreatitis. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 126 Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Viokace · DIN 02241933 Manufacturer: Nestle Enterprises S.A.; listing date 2001-03-07 Health Canada: Marketed since 2020-07-02 · brand VIOKACE · ATC A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) · form Tablet · route Oral · ingredients LIPASE 20880 UNIT, PROTEASE 112500 UNIT, AMYLASE 113400 UNIT · company Nestle enterprises s.a. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Viokace: Formulary list price $0.65 per unit (the source does not state the unit; exact figure $0.6521). What the ministry pays, not the patient.

Ministry pays: $0.6521 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02241933)

Source record
DIN 02241933: Viokace Raw flags: sec12=Y, sec3=Y Item: 561600034; group id 661; item number 1649; lccId 00098; manufacturer id NSA Source form: Tab; strength: 16mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.6521; ministry $0.6521 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02241933 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65603
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (A09AA): coverage varies; not interchangeable

  • Amylase + lipase + protease (Creon Minimicrospheres 35): limited Use 124, 125, 126, 225
Other drugs in the same formulary class (56:16 Digestants) and how they are covered

Matched class: 56:16 Digestants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. No displayed product is listed as a general benefit in this extract. Check its listing requirements below. 56:16 Digestants

LIPASE & AMYLASE & PROTEASE

· 1 products · Limited Use, codes 124, 125, 126, 225 · strengths: 35000 & 35700 & 2240 Units · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:16
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:22 Antiemetics and Antinauseants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE COTAZYM® (pancreatic enzymes) is indicated for the treatment of pancreatic insufficiency attributed to cystic fibrosis, chronic pancreatitis, or any other medically defined pancreatic disease that might require pancreatic enzyme therapy. Geriatrics (> 65 years of age): Clinical studies of COTAZYM® in geriatric patients have not been conducted. Pediatrics (<18 years of age): Post approval, several clinical studies have been conducted supporting the safe and effective use of COTAZYM® in pediatric patients with established pancreatic insufficiency. https://pdf.hres.ca/dpd_pm/00060547.PDF PM date: March 30, 2021 Source product: COTAZYM; DIN 00263818; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.